Cargando…
Use of drug treatment for secondary prevention of cardiovascular disease in urban and rural communities of China: China Kadoorie Biobank Study of 0.5 million people()
AIMS: Relatively little is known about the use of medication for the secondary prevention of cardiovascular disease (CVD) events in China, and the relevance to it of socioeconomic, lifestyle and health-related factors. METHODS AND RESULTS: We analysed cross-sectional data from the China Kadoorie Bio...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991854/ https://www.ncbi.nlm.nih.gov/pubmed/24461961 http://dx.doi.org/10.1016/j.ijcard.2013.12.065 |
_version_ | 1782312509292675072 |
---|---|
author | Chen, Yiping Li, Liming Zhang, Qiuli Clarke, Robert Chen, Junshi Guo, Yu Bian, Zheng Pan, Xianhai Peto, Richard Tao, Ran Shi, Kunxiang Collins, Rory Ma, Liangcai Sun, Huarong Chen, Zhengming |
author_facet | Chen, Yiping Li, Liming Zhang, Qiuli Clarke, Robert Chen, Junshi Guo, Yu Bian, Zheng Pan, Xianhai Peto, Richard Tao, Ran Shi, Kunxiang Collins, Rory Ma, Liangcai Sun, Huarong Chen, Zhengming |
author_sort | Chen, Yiping |
collection | PubMed |
description | AIMS: Relatively little is known about the use of medication for the secondary prevention of cardiovascular disease (CVD) events in China, and the relevance to it of socioeconomic, lifestyle and health-related factors. METHODS AND RESULTS: We analysed cross-sectional data from the China Kadoorie Biobank (CKB) of 512,891 adults aged 30–79 years recruited from 1737 rural and urban communities in China. Information about doctor-diagnosed ischaemic heart disease (IHD) and stroke, and the use of medication for the secondary prevention of CVD events, were recorded by interview. Multivariate logistic regression was used to estimate odds ratios (ORs) for use of secondary preventive treatment, adjusting simultaneously for age, sex, area and education. Overall, 23,129 (4.5%) participants reported a history of CVD (3.0% IHD, 1.7% stroke). Among them, 35% reported current use of any of 6 classes of drug (anti-platelet, statins, diuretics, ACE-I, β-blockers or calcium-channel blockers) for the prevention of CVD events, with the rate of usage greater in those with older age, higher levels of income, education, BMI or blood pressure. The use of these agents was associated positively with history of diagnosed hypertension (OR 7.5; 95% confidence intervals: 7.08–8.06) and diabetes (1.40; 1.28–1.52) and inversely with self-rated health status, but there was no association with years since diagnosis. CONCLUSIONS: Despite recent improvements in hospital care in China, only one in three individuals with prior CVD was routinely treated with any proven secondary preventive drugs. The treatment rates were correlated with the existence of other risk factors, in particular evidence of hypertension. |
format | Online Article Text |
id | pubmed-3991854 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-39918542014-04-23 Use of drug treatment for secondary prevention of cardiovascular disease in urban and rural communities of China: China Kadoorie Biobank Study of 0.5 million people() Chen, Yiping Li, Liming Zhang, Qiuli Clarke, Robert Chen, Junshi Guo, Yu Bian, Zheng Pan, Xianhai Peto, Richard Tao, Ran Shi, Kunxiang Collins, Rory Ma, Liangcai Sun, Huarong Chen, Zhengming Int J Cardiol Article AIMS: Relatively little is known about the use of medication for the secondary prevention of cardiovascular disease (CVD) events in China, and the relevance to it of socioeconomic, lifestyle and health-related factors. METHODS AND RESULTS: We analysed cross-sectional data from the China Kadoorie Biobank (CKB) of 512,891 adults aged 30–79 years recruited from 1737 rural and urban communities in China. Information about doctor-diagnosed ischaemic heart disease (IHD) and stroke, and the use of medication for the secondary prevention of CVD events, were recorded by interview. Multivariate logistic regression was used to estimate odds ratios (ORs) for use of secondary preventive treatment, adjusting simultaneously for age, sex, area and education. Overall, 23,129 (4.5%) participants reported a history of CVD (3.0% IHD, 1.7% stroke). Among them, 35% reported current use of any of 6 classes of drug (anti-platelet, statins, diuretics, ACE-I, β-blockers or calcium-channel blockers) for the prevention of CVD events, with the rate of usage greater in those with older age, higher levels of income, education, BMI or blood pressure. The use of these agents was associated positively with history of diagnosed hypertension (OR 7.5; 95% confidence intervals: 7.08–8.06) and diabetes (1.40; 1.28–1.52) and inversely with self-rated health status, but there was no association with years since diagnosis. CONCLUSIONS: Despite recent improvements in hospital care in China, only one in three individuals with prior CVD was routinely treated with any proven secondary preventive drugs. The treatment rates were correlated with the existence of other risk factors, in particular evidence of hypertension. Elsevier 2014-03-01 /pmc/articles/PMC3991854/ /pubmed/24461961 http://dx.doi.org/10.1016/j.ijcard.2013.12.065 Text en © 2013 The Authors http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/). |
spellingShingle | Article Chen, Yiping Li, Liming Zhang, Qiuli Clarke, Robert Chen, Junshi Guo, Yu Bian, Zheng Pan, Xianhai Peto, Richard Tao, Ran Shi, Kunxiang Collins, Rory Ma, Liangcai Sun, Huarong Chen, Zhengming Use of drug treatment for secondary prevention of cardiovascular disease in urban and rural communities of China: China Kadoorie Biobank Study of 0.5 million people() |
title | Use of drug treatment for secondary prevention of cardiovascular disease in urban and rural communities of China: China Kadoorie Biobank Study of 0.5 million people() |
title_full | Use of drug treatment for secondary prevention of cardiovascular disease in urban and rural communities of China: China Kadoorie Biobank Study of 0.5 million people() |
title_fullStr | Use of drug treatment for secondary prevention of cardiovascular disease in urban and rural communities of China: China Kadoorie Biobank Study of 0.5 million people() |
title_full_unstemmed | Use of drug treatment for secondary prevention of cardiovascular disease in urban and rural communities of China: China Kadoorie Biobank Study of 0.5 million people() |
title_short | Use of drug treatment for secondary prevention of cardiovascular disease in urban and rural communities of China: China Kadoorie Biobank Study of 0.5 million people() |
title_sort | use of drug treatment for secondary prevention of cardiovascular disease in urban and rural communities of china: china kadoorie biobank study of 0.5 million people() |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991854/ https://www.ncbi.nlm.nih.gov/pubmed/24461961 http://dx.doi.org/10.1016/j.ijcard.2013.12.065 |
work_keys_str_mv | AT chenyiping useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople AT liliming useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople AT zhangqiuli useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople AT clarkerobert useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople AT chenjunshi useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople AT guoyu useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople AT bianzheng useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople AT panxianhai useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople AT petorichard useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople AT taoran useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople AT shikunxiang useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople AT collinsrory useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople AT maliangcai useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople AT sunhuarong useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople AT chenzhengming useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople AT useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople |